Research Report: MDR

We continue to remain very bullish on MDR even after the reaction to 1Q19 earnings, and think that the forward P/E of 3.6x (based on 2020 and beyond EPS) indicates that it has been too overly-punished. This is a strong buy.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.